Annals of Oncology · 2017 · 154 citations · 17 references
Life SciencesImmunologyInternal MedicineImmunopathologyImmunotherapyInflammationAutoimmune DiseasesAutoimmune InflammationGastrointestinal ImmunologyGastrointestinal InflammationImmune Checkpoint InhibitorsImmune-mediated Inflammatory DiseasesAntibodiesPd-1 SignalingProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-ligand 1 Inhibitors
17
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17